Navigating the shift: Financial due diligence in a rescheduled cannabis market

As the cannabis industry matures, the era of high-risk, cash-heavy speculation is giving way to a more sophisticated landscape defined by institutional rigor and fiscal discipline. Two primary catalysts are driving this evolution: the historic move toward federal rescheduling and a critical "debt wall" facing certain operators in 2026. For accounting and finance professionals, these shifts elevate financial due diligence from a checklist exercise to a strategic, decision-oriented analysis.

Federal rescheduling: The impact on M&A

The Department of Justice’s recent reclassification of medical cannabis and FDA approved products from Schedule I to Schedule III of the Controlled Substances Act represents the most consequential change in federal cannabis policy in decades. For M&A stakeholders, the primary impact is the removal of the Section 280E tax burden.  

On June 29, 2026, the Drug Enforcement Administration (DEA) will commence an administrative hearing to determine whether all remaining cannabis, primarily adult use (recreational) marijuana, should be reclassified from Schedule I to Schedule III under the Controlled Substances Act. The hearing is scheduled to conclude no later than July 15, 2026. Following the close of the hearing, the presiding Administrative Law Judge will issue a recommended decision. Final authority rests with the DEA Administrator, subject to Department of Justice oversight. Most legal observers anticipate that a final agency decision will be issued in fall 2026.

For sellers: Valuation and margin recovery

Previously, Section 280E prohibited cannabis businesses from deducting ordinary business expenses (like marketing, rent, and payroll) from their gross income. This forced companies to pay federal taxes on gross profit rather than net income, often resulting in effective tax rates of 70% or higher.     

• Regulatory bifurcation: Medical cannabis (state-licensed) is now Schedule III while adult-use remains Schedule I. Meaning, for operators that service medical and adult-use consumers, this creates material valuation and structural differences inside the same company as these assets are now priced differently. To preserve and maximize value, sellers must demonstrate clean segregation of medical and adult use accounting, cash flows, and licenses.

For buyers: Lower cost of capital and strategic entry

•  Improved cash flow: Buyers are no longer acquiring a business that is "taxed to death" (at least not for medical cannabis). The improved cash flow profiles allow for more aggressive acquisition strategies and easier debt servicing.  
• Institutional interest: Rescheduling lowers the reputational and regulatory risk for traditional private equity and institutional lenders. Due diligence must now meet institutional standards.

Cannabis M&A deal flow: Current trends and 2026 forecasts  

While 2024 and 2025 saw a relative cooling of the M&A market  due to high interest rates and pricing compression, 2026 is emerging as a year of "forced consolidation" and strategic "right-sizing" in the cannabis space.

The 2026 debt wall

A major driver of current deal flow is the approximately $6 billion in debt maturing across the U.S. cannabis sector by the end of 2026.  

• Distressed M&A: Many multi-state operators (MSOs) are selling off non-core licenses and retail footprints to satisfy lenders. This creates a "buyer’s market" for well-capitalized firms looking to expand their geographic footprint at a discount.  
• Normalization of growth: Experts forecast legal revenues to reach approximately $30.5 billion in 2026, a steady but maturing growth rate of around 5%  . The era of "growth at any cost" has ended; buyers are now looking for sustainable unit economics rather than just top-line expansion.  

The bottom line

The rescheduling of cannabis is not just a legal victory; it is a financial reset. For firms navigating an acquisition or preparing for exit, rigorous and forward-looking financial due diligence is the only way to bridge the gap between today’s uncertainty and tomorrow’s institutional-grade market.

To learn how rescheduling affects your valuation or to discuss our M&A advisory services, contact our Cannabis Industry Group .